- Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
- Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
- Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
- Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
- Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade Glioma
- Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Highlights
- Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy Candidate
- CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade Glioma
- Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and Catalysts
More ▼
Key statistics
On Friday, Candel Therapeutics Inc (CADL:NMQ) closed at 11.50, -19.58% below its 52-week high of 14.30, set on May 16, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 13.15 |
---|---|
High | 13.18 |
Low | 11.05 |
Bid | 11.60 |
Offer | 11.63 |
Previous close | 12.70 |
Average volume | 1.01m |
---|---|
Shares outstanding | 29.35m |
Free float | 19.16m |
P/E (TTM) | -- |
Market cap | 299.34m USD |
EPS (TTM) | -1.31 USD |
Data delayed at least 15 minutes, as of May 17 2024 21:00 BST.
More ▼